Jump to Main Contents
国立がん研究センター 中央病院

Home > ATLAS Project Research Members

ATLAS Project Research Members

National Cancer Center Hospital (Tokyo, Japan)

NOGUCHI Emi (Depertment of Medical Oncology)

NOGUCHI Emi

NOGUCHI Emi MD, PhD 

Dr. NOGUCHI's story

Dr. Noguchi is a medical oncologist specializing in breast cancer and gynecologic cancer research and treatment. She is an investigator and a steering committee member for the Asian investigator-initiated randomized phase III trial for hormone-receptor positive, HER2-negative metastatic breast cancer (PATHWAY trial, NCT03423199). She is an active member of the national cooperative group, the Japan Clinical Oncology Group (JCOG) and serves on the Clinical Trials Working Group of the JCOG Breast Study Group.

Research interests

Dr. Noguchi studies clinical trial design, cancer drug development, and affordable cancer care.

Professional Experiences

  • 2021-Present Head of Physicians, Department of Medical Oncology, National Cancer Center Hospital
  • 2016-2021 Staff Physician,  Department of Breast and Medical Oncology, National Cancer Center Hospital
  • 2014-2016 Reviewer, Office of New Drug V, Pharmaceuticals and Medical Devices Agency
  • 2012-2014 Chief Resident, Department of Breast and Medical Oncology, National Cancer Center Hospital

Selected publications

  1. Noguchi E, Shien T, Iwata H. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. Jpn J Clin Oncol. 2021;51(3):321-332.
  2. Sagara Y, Mori M, Yamamoto S, Eguchi K, Iwatani T, Naito Y, Kogawa T, Tanaka K, Kotani H, Yasojima H, Ozaki Y, Noguchi E, Miyasita M, Kondo N, Niikura N, Toi M, Shien T, Iwata H. Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer. Oncologist. 2021;26(4):e686-e693.
  3. Bun S, Yonemori K, Sunadoi H, Nishigaki R, Noguchi E, Okusaka T, Nishida T, Fujiwara Y. Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncol Pract. 2021;17(3):e416-e425.
  4. Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, Takahashi K, Okamoto A, Hirabayashi S, Hasegawa D, Manabe A, Ono K, Matsuoka M, Arai Y, Togashi Y, Shibata T, Nishikawa H, Aoki K, Yamamoto N, Kohno T, Ogawa C. Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. N Engl J Med. 2021;384(1):42-50.
  5. Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Rep Oncol Med. 2020;2020;25:18383
  6. Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K. Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. Case Rep Oncol Med. 2020;2020;25:18383
  7. Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A, Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020;126(1):98-104.
  8. Noguchi E, Tamura K, Hattori M, Horiguchi J, Sato N, Kanatani K, Matsunaga K, Iwata H, Fujiwara Y. Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. Breast Cancer. 2019;26(1):39-46.

Link

 

Photo

NOGUCHI Emi 2